Thomas A. Hensing

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

Glenwood Goss, Chris J. O’Callaghan, Ian Lorimer et al. · Journal of Clinical Oncology · 2013 · 359 citations · Full text

Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research

Rogério Lilenbaum, John Cashy, Thomas A. Hensing et al. · Journal of Thoracic Oncology · 2008 · 217 citations

Cancer Epidemiology, Medicine, Epidemiology Of Cancer +8

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Don S. Dizon, Lada Krilov, Ezra E.W. Cohen et al. · Journal of Clinical Oncology · 2016 · 212 citations

Medicine, Cancer Management, Pathology +7

Treatment of Stage IV Non-small Cell Lung Cancer

Mark A. Socinski, Tracey L. Evans, Scott Gettinger et al. · CHEST Journal · 2013 · 190 citations · Full text

Medicine, Pulmonary Blastoma, Oncology +2

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Thomas A. Hensing, Alfred Rademaker et al. · Journal of Clinical Oncology · 2009 · 179 citations · Full text